Gambogic acid ACAS# 1592842-93-7 |
2D Structure
Quality Control & MSDS
Package In Stock
Number of papers citing our products
Cas No. | 1592842-93-7 | SDF | Download SDF |
PubChem ID | N/A | Appearance | Powder |
Formula | C39H48O10 | M.Wt | 676.8 |
Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Gambogic acid A Dilution Calculator
Gambogic acid A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.4775 mL | 7.3877 mL | 14.7754 mL | 29.5508 mL | 36.9385 mL |
5 mM | 0.2955 mL | 1.4775 mL | 2.9551 mL | 5.9102 mL | 7.3877 mL |
10 mM | 0.1478 mL | 0.7388 mL | 1.4775 mL | 2.9551 mL | 3.6939 mL |
50 mM | 0.0296 mL | 0.1478 mL | 0.2955 mL | 0.591 mL | 0.7388 mL |
100 mM | 0.0148 mL | 0.0739 mL | 0.1478 mL | 0.2955 mL | 0.3694 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 10-Hydroxyaloin B
Catalog No.:BCN0823
CAS No.:134863-92-6
- 10-Methoxygambogenic acid
Catalog No.:BCN0822
CAS No.:2095102-72-8
- 3beta-Hydroxyurs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester
Catalog No.:BCN0821
CAS No.:434942-42-4
- 3beta-(alpha-L-Arabinopyranosyloxy)urs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester
Catalog No.:BCN0820
CAS No.:435269-07-1
- Barbaloin-related compound B
Catalog No.:BCN0819
CAS No.:473225-22-8
- Barbaloin-related compound A
Catalog No.:BCN0818
CAS No.:473225-21-7
- Dehydrodicatechin A
Catalog No.:BCN0817
CAS No.:36048-23-4
- Senkyunolide N
Catalog No.:BCN0816
CAS No.:140694-58-2
- Cajanine
Catalog No.:BCN0815
CAS No.:87402-84-4
- 4-Methoxybenzoylacetic acid
Catalog No.:BCN0814
CAS No.:13422-77-0
- Elgonica dimer A
Catalog No.:BCN0813
CAS No.:132210-48-1
- Rhusflavanone
Catalog No.:BCN0811
CAS No.:53060-72-3
- 10-Carboxyloganin
Catalog No.:BCN0825
CAS No.:182172-02-7
- Oblonganoside D
Catalog No.:BCN0826
CAS No.:943021-91-8
- Cannabisin P
Catalog No.:BCN0827
CAS No.:2756983-19-2
- Pinocembrin 7-O-(4'',6''-hexahydroxydiphenoyl)-beta-D-glucose
Catalog No.:BCN0828
CAS No.:1825287-22-6
- Oxytroflavoside E
Catalog No.:BCN0829
CAS No.:1391144-84-5
- 12beta-Acetoxy-3beta-hydroxy-7,11,15,23-tetraoxo-lanost-8,20-diene-26-oic acid
Catalog No.:BCN0830
CAS No.:1085338-75-5
- Oxytroflavoside A
Catalog No.:BCN0831
CAS No.:1391144-80-1
- Gardoside methyl ester
Catalog No.:BCN0832
CAS No.:93930-20-2
- Ganoderenic acid K
Catalog No.:BCN0833
CAS No.:942950-94-9
- 2,6-Dihydroxyacetophenone-4-O-[4',6'-(S)-hexahydroxydiphenoyl]-beta-D-glucose
Catalog No.:BCN0834
CAS No.:1781226-44-5
- Ganolucidic acid D
Catalog No.:BCN0835
CAS No.:102607-22-7
- Rhamnocitrin 3-galactoside
Catalog No.:BCN0836
CAS No.:99878-05-4
Gambogic Acid and Piperine Synergistically Induce Apoptosis in Human Cholangiocarcinoma Cell via Caspase and Mitochondria-Mediated Pathway.[Pubmed:35600948]
Evid Based Complement Alternat Med. 2022 May 12;2022:6288742.
Most cholangiocarcinoma (CCA) patients undergo chemotherapy as a therapeutic approach due to the disease's frequently late diagnosis. However, because CCA is resistant to currently available treatments, the prognosis for this cancer is still quite poor. Combination therapy has emerged as a novel and promising strategy in cancer treatment, as monotherapy frequently results in tumor recurrence and drug resistance. Gambogic acid has been shown to have a synergism with other compounds in combating certain cancer cells. Moreover, piperine has been shown to improve the efficacy of numerous chemotherapy drugs and other anticancer natural substances. However, no research has been done on the combination of these two compounds in the treatment of bile duct cancer. In this study, the cytotoxic activity was determined by using the MTT assay, and then, the combined effect was assessed by using the combination index (CI). We found that the combination of Gambogic acid And piperine inhibited cell viability more effectively than either treatment alone, and it also demonstrated a synergistically cytotoxic effect against CCA cells. Interestingly, the findings allowed the use of lower concentrations of gambogic acid in cancer treatment when combined with piperine, which could reduce its adverse effect on normal cholangiocytes. Furthermore, the combination of the two compounds increased CCA cell death by inducing apoptosis via both the extrinsic and intrinsic or mitochondria-mediated pathways, as determined by caspase-3, -8, and -9 activity and the reduction of mitochondrial transmembrane potential (DeltaPsim). It is possible that the use of these two natural compounds together could be a promising strategy for the treatment of bile duct cancer.
Research Progress in the Field of Gambogic Acid and Its Derivatives as Antineoplastic Drugs.[Pubmed:35566290]
Molecules. 2022 May 4;27(9). pii: molecules27092937.
Gambogic acid (GA) is a natural product with a wide range of pharmacological properties. It plays an important role in inhibiting tumor growth. A large number of GA derivatives have been designed and prepared to improve its shortcomings, such as poor water solubility, low bioavailability, poor stability, and adverse drug effects. So far, GA has been utilized to develop a variety of active derivatives with improved water solubility and bioavailability through structural modification. This article summarized the progress in pharmaceutical chemistry of GA derivatives to provide a reference and basis for further study on structural modifications of GA and expansion of its clinical applications.